AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04698122 — intervention group
Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
Study NCT04698122 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Study NCT04698122 — intervention group
Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study NCT05242419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection
Description: 0.9% Sodium Chloride Injection
Study NCT05242419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A Injection
Description: Huperzine A Injection
Study NCT06646588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.
Study NCT06646588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: intravenous drip 200mg，day1，once every three weeks.
Study NCT06646588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy synchronised with drugs.
Study NCT05812547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen
Description: subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
Study NCT05812547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose monitoring mobile app
Description: The control group will use a designated glucose monitoring mobile app to record their glucose levels
Study NCT06090318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: 260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
Study NCT05314569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine- dexmedetomidine
Description: ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery
Study NCT05314569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl- midazolam
Description: Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
Study NCT05314569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoflurane
Description: Anesthetic inhalational gas
Study NCT05564949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD
Description: Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
Study NCT06409026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
Study NCT06355986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert-based computerized decision support
Description: An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
Study NCT05709834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic training
Description: Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination
Study NCT05709834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: Patients will receive conventional treatment
Study NCT04798976 — intervention group
Intervention type: DRUG
Intervention: neoadjuvant/adjuvant therapy
Description: chemotherapy/endocrine therapy/surgery/radiotherapy
Study NCT05663294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beams radiotherapy
Description: External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours).
Study NCT05663294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR.
Study NCT04933955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulp therapy
Description: pulpotomy
Study NCT05556863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELA026
Description: Single dose of ELA026
Study NCT05556863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELA026
Description: Multiple doses of ELA026
Study NCT04791228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-Guided High Intensity Focused Ultrasound
Description: Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy.
Study NCT04791228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyso-thermosensitive Liposomal Doxorubicin
Description: LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence.
Study NCT04557462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Capsule 200 mg (b.i.d.) taken orally twice a day
Study NCT05586542 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DERMASEAL
Description: a novel skin substitute formulated as planar, thin film
Study NCT05586542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Film
Description: a planar, thin film made from human plasma
Study NCT05586542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
Study NCT05586542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
Study NCT06512155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery
Study NCT06512155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Take zolpidem 10mg qn from two days before surgery to three days after surgery
Study NCT05160051 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET Scan
Description: 68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
Study NCT06201962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage applications will be performed for 15 minutes every morning and evening for two days.
Study NCT06201962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Description: In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.
Study NCT06201962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
Study NCT04675476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Prompt & Patient Outreach and Education
Description: To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
Study NCT06090318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1680mg administered every 4 weeks
Study NCT05854472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone based application use
Description: A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
Study NCT05403580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO
Study NCT05403580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Given PO
Study NCT05403580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05403580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05403580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05903469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Attitude Test
Description: The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
Study NCT05903469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implicit Attitude Test
Description: The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
Study NCT05406479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP (Bedaquiline)
Description: Single dose of Bedaquiline
Study NCT05406479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDR-PEP
Description: Single dose of Rifampicin
Study NCT05406479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP (Rifampicine)
Description: Single dose of Rifampicin
Study NCT05185037 — intervention group
Intervention type: DEVICE
Intervention: Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)
Description: The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
Study NCT04709146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Audio-Vestibular evaluation
Description: Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
Study NCT06211686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein powder and Resistance exercise
Description: 1. Protein powder supplementation 25-30 g/day~2. Resistance exercise 2 time/week
Study NCT05918120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Sleep Apnea Test
Description: Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
Study NCT05918120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory polysomnography
Description: Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
Study NCT05878639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 bottles of Lactulose oral solution
Description: Patients will take lactulose for bowel preparation.
Study NCT05878639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3L-polyethylene glycol
Description: Patients will take 3L-polyethylene glycol for bowel preparation.
Study NCT05870800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
Description: Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
Study NCT05870800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Study NCT05870800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Study NCT04542343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in knowledge, motivation, skills, resources
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
Study NCT06495775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quickfact
Description: fecal sampling
Study NCT05278273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurotrackerX
Description: At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
Study NCT05194774 — intervention group
Intervention type: PROCEDURE
Intervention: Greater Trochanter epiphysiodesis
Description: epiphysiodesis by cortical screw and washer
Study NCT06333925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)
Description: 10 Hz rTMS over the right dorsal lateral prefrontal cortex (dlPFC)
Study NCT06333925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)
Description: inactive rTMS over the right dorsolateral prefrontal cortex (dlPFC)
Study NCT06333925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
Study NCT06333925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
Study NCT03833206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study NCT05472233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture removal after Coronally Positioned Flap
Description: Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
Study NCT05472233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal after Coronally Positioned Flap
Description: Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
Study NCT04827212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Companion
Description: Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time.
Study NCT05118737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
Study NCT05118737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab